ClinicalTrials.gg
CompletedNCT07839000Updated Sep 24, 2026

A Clinical Trial to Evaluate [14C]-MK-4208/[14C]-TERN-701 in Healthy Adult Male Participants (MK-4208-002/TERN701-1016)

A Phase 1 interventional study of TERN-701 in Healthy, sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Feb 2026, registered Sep 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The goal of the study is to learn what happens to different forms of TERN-701 medications in a healthy person's body over time. Researchers will compare what happens to different forms of TERN-701 in a person's body over time.

The goal of the study is to learn:

  • What happens to different forms of TERN-701 in a person's body over time.
  • The amount and number of different forms of TERN-701 that leave a person's body over time.
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

First submitted after Terns, Inc. became part of Merck & Co., Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has (BMI) ≥18.5 and ≤32.0 kg/m\^2
  • Is in good health

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has history or presence of any medical condition or prior surgery that may impact typical absorption, distribution, metabolism, or excretion of the orally administered study drug (e.g., gastric bypass, gastrointestinal dysmotility, irritable or inflammatory bowel disease)
  • Has history or laboratory evidence of hyperthyroidism (thyroid-stimulating hormone [TSH] \< lower limit of normal [LLN]) or hypothyroidism (TSH ≥8 mIU/L)
  • Has history of cancer that has not been in complete remission for > 5 years (except basal cell skin cancer or squamous cell skin cancer with a history of curative treatment and no recurrence for > 1 year prior)
  • Has history of dysphagia, aspiration, or other conditions that could potentially impede the ability to safely orally ingest the study drug per protocol
  • Has history of incomplete bladder emptying with voiding (i.e., urinary retention) or recent history of awakening more than once at night to void
  • Has usual habit of \< 1 or > 3 bowel movements per day
  • Has family history of long syndrome or of unexplained sudden death in a first-degree relative under 50 years of age
  • Has documented congenital or acquired long QT syndrome
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    [14C]-TERN-701

    Participants receive a single oral dose of radiolabeled TERN-701 (\[14C\]-TERN-701) on Day 1.

    Drug: TERN-701

Interventions

  • Oral Liquid radiolabeled with \[14C\]-TERN-701

    Also known as: MK-4208, HS-10382

06

What researchers measure

Primary outcomes

  1. Percentage of Total Amount of [14C]-Radiolabel Excreted into Urine per Sampling Interval (Aeurine,14C,t1-t2)

    Urine will be collected to determine the Aeurine,14C,t1-t2 of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  2. Cumulative Percentage of Total Amount of [14C]-Radiolabel Excreted into Urine up to the Last Sampling Interval (Aeurine,14C)

    Urine will be collected to determine the Aeurine,14C of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  3. Percentage of Total Amount of [14C]-Radiolabel Excreted into Feces per Sampling Interval (Aefeces,14C,t1-t2)

    Feces will be collected to determine the Aefeces,14C,t1-t2 of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  4. Cumulative Percentage of Total Amount of [14C]-Radiolabel Excreted into Feces Up to the Last Sampling Interval (Aefeces,14C)

    Feces will be collected to determine the Aefeces,14C of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  5. Percentage of Total Amount of [14C]-Radiolabel Excreted from Body per Sampling Interval (Aetotal, 14C, t1-t2)

    Urine and Feces will be collected to determine the Aetotal,14C,t1-t2 of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  6. Cumulative Percentage of Total Excretion of [14C]-Radiolabel from the Body (Aetotal, 14C)

    Urine and Feces will be collected to determine the Aetotal,14C of radiolabeled \[14C\]-TERN-701. Calculated as, Aetotal,14C= Aeurine,14C +Aefeces,14C.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  7. Maximum Concentration Observed in Plasma (Cmax) of TERN-701 in Plasma

    Blood samples will be collected to determine the Cmax of TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  8. Time to Maximum Concentration Observed in Plasma (Tmax) of TERN-701 in Plasma

    Blood samples will be collected to determine the Tmax of TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  9. Apparent Terminal Half-Life (t1/2) of TERN-701 in Plasma

    Blood samples will be collected to determine the t1/2 of TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  10. Area Under the Concentration-Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) of TERN-701 in Plasma

    Blood samples will be collected to determine the AUC0-Last of TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  11. Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-Inf) of TERN-701 in Plasma

    Blood samples will be collected to determine the AUC0-inf of TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  12. Apparent Oral Clearance (CL/F) of TERN-701 in Plasma

    Blood samples will be collected to determine the CL/F of TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  13. Apparent Volume of Distribution (Vz/F) of TERN-701 in Plasma

    Blood samples will be collected to determine the Vz/F of TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  14. Total [14C]-Radiolabel in Plasma

    Blood samples will be collected to determine the Total \[14C\]-Radiolabel, calculated as the AUCinf of non-radiolabeled TERN-701 in plasma divided by the AUCinf of total \[14C\]-radiolabel in plasma.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  15. Tmax of Total [14C]-Radiolabel in Plasma

    Blood samples will be collected to determine the Tmax of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  16. t1/2 of Total [14C]-Radiolabel in Plasma

    Blood samples will be collected to determine the t1/2 of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  17. AUC0-last of Total [14C]-Radiolabel in Plasma

    Blood samples will be collected to determine the AUC0-last of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  18. AUC0-Inf of Total [14C]-Radiolabel in Plasma

    Blood samples will be collected to determine the AUC0-Inf of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  19. Cmax of Total [14C]-Radiolabel in Plasma

    Blood samples will be collected to determine the Cmax of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  20. Tmax of Total [14C]-Radiolabel in Whole Blood

    Blood samples will be collected to determine the Tmax of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  21. t1/2 of Total [14C]-Radiolabel in Whole Blood

    Blood samples will be collected to determine the t1/2 of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  22. AUC0-last of Total [14C]-Radiolabel in Whole Blood

    Blood samples will be collected to determine the AUC0-last of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  23. AUC0-Inf of Total [14C]-Radiolabel in Whole Blood

    Blood samples will be collected to determine the AUC0-Inf of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  24. Cmax of Total [14C]-Radiolabel in Whole Blood

    Blood samples will be collected to determine the Cmax of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  25. Cumulative Amount of Total [14C]-Radiolabel Excreted in Urine (Aeurine)

    Urine samples will be collected to determine the Aeurine of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  26. Renal Clearence (CLr) of [14C] radioactivity

    Urine samples will be collected to determine the CLr of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  27. Percent of Dose Excreted as Radioactivity in Urine (%Feurine) of [14C] radioactivity

    Urine samples will be collected to determine the %Feurine of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  28. Cumulative Amount of Total [14C]-Radiolabel Excreted in Feces (Aefeces) of [14C] radioactivity

    Feces samples will be collected to determine the Aefeces of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  29. Percent of Dose Excreted as Radioactivity in Feces (%Fefeces) of [14C] radioactivity

    Feces samples will be collected to determine the %Fefeces of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  30. Percentage Area Under the Concentration-Time Curve (AUC) of [14C]-Radiolabel TERN-701 Metabolite in Plasma

    Blood samples will be collected to determine the Percentage of AUC of \[14C\]-radiolabel TERN-701 metabolite in plasma.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  31. Percentage of Administered Dose of [14C]-Radiolabel TERN-701 Metabolite in Feces

    Feces samples will be collected to determine the percentage of administered dose of \[14C\]-radiolabel TERN-701 metabolite in feces.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  32. Percentage of the [14C]-Radiolabel TERN-701 Metabolite in Urine

    Urine samples will be collected to determine the percentage of \[14C\]-radiolabel TERN-701 metabolite in urine.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

Secondary outcomes

  1. Mean concentration of [14C]-TERN-701 Elimination

    Blood, Feces, and Urine samples will be collected to determine the mean concentration of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  2. Rate of Elimination of [14C]-TERN-701

    Blood, Feces, and Urine samples will be collected to determine the Rate of Elimination of radiolabeled \[14C\]-TERN-701.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  3. Whole Blood to Plasma Total [14C]-Radiolabel AUC Ratio

    Blood samples will be collected to determine the Whole Blood to Plasma AUC Ratio. Calculated as AUC0-Inf of total \[14C\]-radiolabel in whole blood divided by the AUC0-Inf of Total \[14C\]-Radiolabel in Plasma.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  4. Number of TERN-701 Metabolite in ≥10% of Total Exposure of [14C]-Radiolabel in Plasma

    Blood samples will be collected to determine the number of TERN-701 metabolite that account for ≥10% of total drug-related radiolabeled \[14C\]-TERN-701 exposure in plasma.

    Time frame: Pre-dose and at designated time points up to 408 hours post dose

  5. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 49 days

  6. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study due to an AE will be reported.

    Time frame: Up to approximately 18 days

07

Study locations

1 site
  • Pharmaron CPC Inc
    Baltimore, Maryland 21201, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Apr 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Sep 24, 2026
StartActual
Feb 25, 2026
Primary completionActual
Apr 3, 2026
CompletionActual
Apr 3, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07839000
Responsible party
Sponsor
First posted
Sep 24, 2026
Start date
Feb 25, 2026
Primary completion
Apr 3, 2026
Completion
Apr 3, 2026
Last update
Sep 24, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Embibatinib

Start the discussion